GH56 study for MTAP-deleted advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called GH56 in patients with advanced solid tumors that have lost a specific gene called MTAP. The drug aims to target these tumors, and the study will find out if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old
- You have a type of cancer that has spread and standard treatments either did not work or you could not tolerate them
- Your tumor shows loss of the MTAP gene (a special test on your tumor sample is needed)
- You have at least one tumor that can be measured by scans
- You are physically able to take care of yourself (ECOG score 0 or 1) and expected to live at least 12 weeks
- Your organs (like liver, kidneys) are functioning well enough, and you agree to use contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called HS-10587 for people with advanced solid tumors that have a specific genetic change (MTAP deletion) and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Hear when a new Advanced Solid Tumors With MTAP Deletion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.